-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Omega Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
- Omega Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$16.4M, a 28.3% increase year-over-year.
- Omega Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$74.2M, a 32.9% increase year-over-year.
- Omega Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$100M, a 2.44% increase from 2022.
- Omega Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$103M, a 55.6% decline from 2021.
- Omega Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$66M, a 131% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)